MedTrace Logo

Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults

NCT00921206 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-09-23

No results posted yet for this study

Summary

The objective is to assess the humoral and cellular immune response of the VAX102 vaccine delivered IM and SC in a prime-boost regimen at dose levels 1 µg or 2 µg in healthy adults against the influenza A virus M2e antigen after each vaccination.

Conditions

Interventions

BIOLOGICAL

VAX102

1 ug i.m. compared to 2 ug s.c.

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • VaxInnate Corporation

    lead INDUSTRY

Principal Investigators

  • Edward Janoff, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00921206 on ClinicalTrials.gov